Samsung BioLogics Wins Patent Invalidation Action Against Lonza
Avalue Smart Ward – the Total Care Platform for Unimpeded Communication in Healthcare
Hallym University Sacred Heart Hospital holds '2019 Endocrinology Seminar for Medial Practitioners'
Gene Information Fabric and Human Pass Sign Contract to Establish Joint Venture for Construction of Global Gene Platform
Korean Heart Rhythm Society Hosted Announcement Press Conference of the Survey on Recognition of Arrhythmia Diseases
Cloud Computing Empowers Healthcare Institutions in Asia Pacific
Janssen Receives Complete Response Letter From U.S. FDA For Sirukumab Biologics License Application
FDA approves Mavyret for Hepatitis C
FDA Issues Emergency Use Authorization for Thermo Fisher Scientific's Zika Virus Assay
Korean Society of Gastrointestinal Endoscopy Held ‘Great Endoscope’ Campaign Launching Press Conference
Korea Agilent Technologies Office Building Open House
On February 16 morning, Korea Agilent Technologies corp. held commemoration for opening a new office building, and announced that it opened a new Korea head office building at Hannam-dong, Yongsan-gu, Seoul. Office building open house event, held in the morning, started with taking Korean traditional ‘gosa(offering a sacrifice to spirits),’ and went along in order of ribbon cutting, partners’ visiting the building and etc. A new office building of Korea branch of Agilent Technologies is opened for satisfying Korean government’s policy, which is strategic focusing on life science, health care, medicine, food and environment field. It aims for satisfying Agilent clients’ requirements seeking for extending prospect of science technology and innovation. In the building, there are high-tech analysis laboratory and customer training center with the size of about 50 square meters(540 square feet). Agilent has a plan of providing support to business support of domestic clients and training talented individuals by using main facilities prepared in the new office building. Especially, ‘Agilent University program’ is expected to contribute to the company’s main solutions aimed at business, institutions, students and etc. Facilities for the program are directly connected from the lobby in new office building, so it’s expected to be used in the future. ▲ Korea Agilent Technologies Yong-seung Shin director was in charge of introducing office building. ▲ ‘Agilent University’ is being operated in order to induce recent solutions to be skillful. ▲ There is even cleanroom facility in ‘Agilent University’ facility. ▲ Specimen chamber and supplementary equipment are prepared at the level of site in business world for ‘Agilent University’ facility. ▲ Workstations and monitors operated in connection are equipped with only products of HP. ▲ The office is configured in separated and individual form that space for each employee is divided. ▲ There is also a lounge facility for staffs and visitors. ▲ On the opposite site of the lounge, there is place of education in a form of classroom. ▲ Along the passage of Korea Agilent Technologies office, corporation history, slogans, and mottos are drawn.
Korea Agilent Technologies New Office Building Opening Commemoration Press Conference
On February 16 morning, Korea Agilent Technologies corp. held commemoration for opening a new office building, and announced that it opened a new Korea head office building at Hannam-dong, Yongsan-gu, Seoul. Built on the site where Daum Hannam office building with about 3,630 square meters(39,000 square feet) was placed, a new office building of Korea branch of Agilent Technologies is opened for satisfying Korean government’s policy, which is strategic focusing on life science, health care, medicine, food and environment field. It aims for satisfying Agilent clients’ requirements seeking for extending prospect of science technology and innovation. Possessing high availability by being placed between representative business districts Kangnam-gu and Jongro-gu, Agilent’s new Korea head office has high-tech analysis laboratory and customer training center with the size of about 50 square meters(540 square feet). Agilent is going to provide a wide range of service aimed at fields having high importance in domestic such as from further medicine, disease research and diagnosis to agriculture, food, environment, and semiconductor. ▲ Korea Agilent Technologies Austin Kim CEO. CEO of Korea Agilent Technologies, Austin Kim said “There is a high correlation between our company’s goals to seeking for new findings improving the quality of life and country leading innovation in various fields such as life science, application market, and healthcare. He added “This year, we are aiming for accomplishing innovative results with association technology based on cooperation of domestic research teams, and contributing to Korea’s development and the quality of life.” Also, “We chose this place for the new head office by consideration that this place could create ideal environment quickly responding to clients’ requirements and promoting teamwork and cooperation.” And “I have great expectation for showing high-tech analysis laboratory and training center to provide better service to clients.” ▲ Main solutions are provided to the best six categories. Austin said that healthcare product consumer seeking for wise consumption, development of new medicine and seeking innovation, and improvement of the quality of consumer product are the core powers of industry where Agilent currently works as a main center. To associated global market estimated as the scale of $45 billion, Agilent is providing analysis equipment, consumables, software, and excellent total workflow solution consisted of service to laboratory, and sales at Asia-pacific region sizes up to 33% of total revenue. In 1984, Agilent had once been in Korea before being separated from Hewlett Packard(HP), and stated German separate entity in 1999. At the end of 2014, an electronic measuring instrument department(Key-sight Technologies) was separated. Korea head office which is newly opened in Hannam-dong by Agilent that has built its position as global leading company in the field of life science, diagnosis, and applied chemistry is demonstrating unwavering will toward domestic market. ▲ Main solutions such as Dako, cross lab, and open lab are playing active parts in industry site. This year’s main goal that Korea Agilent Technologies set to support domestic clients is mass spectrometry, intensified client training, application support program and etc. It makes a new office building of integrated Korean branch have control over capital area in Korea. For supporting clients in other places than capital area, it is also managing the branch in Daejeon. ▲ There was a question and answer session after presentation. After Korea Agilent Technologies Austin Kim’s presentation, question and answer session that branch manager and Lon Justice, a vice president of Agilent Technologies global client experience/business/marketing and management, participate was followed. Q1. (Acrofan)There are domestic institutes and colleges belonging to international network. Korea is currently researching of international projects such as MERS, which was a great issue in the last year, and Ebola. Introduce us if there is any precedent collaboration with these institutions. (Austin) We are working on collaboration with global program. Focusing on not only academic, but also collaboration with a leading company in business world. In Korea, as a part of this, there are many researches. Things with the word ‘mix’ behind a related noun are the example of them, and they deal with complicated parts. Also, Korean clients tend to prefer very much high-end, so we have common partnership with a prominent university. We use technologies in lab, and make them be used in diagnosis at the real site. (Lon Justice) Infra for every country is important in global collaboration program. The product is provided to not only Korea, but also Germany, the US, and Australia, and we are supported to collaborate with local teams and these corporations or directly exchange. Agilent has been invested very early to Asia market, and its joint development is deeply related to not only academic but also clients. Q2. (Acrofan) Industry of new medicine/solution development around large hospitals and building medicine production equipment led by a large company are on the rise at industrial level. Please introduce growth prospects and any solution from your company which is expected to be mainly provided. (Austin) In Korea, when I say a large hospital, the best five hospitals are famous. There is a part of clinical research, and we enter the real production after diagnosis here. In this process, if it is possible to support all the work process solutions, it will enter Q/A field. When we check if the sample is safe, we support and provide solutions through hospital’s international partnership.
Institut Pasteur Korea 2015 Press Conference
During a press conference held at Korea Press Center on November 2, 2015, Institut Pasteur Korea(CEO: Dr. Hakim Djaballah) addressed the current research status on MERS(Middle East Respiratory Syndrome) and Ebola virus infections as well as strategies to tackle potential public health threat triggered by either MERS and Ebola virus infections. Institut Pasteur Korea, located in Pangyo, was founded in 2004. It is a private institution devoted to discovery biology for infectious diseases. Institut Pasteur Korea’s unique translational capabilities and small molecule intervention technology make it possible to rapidly address unmet global health needs through diagnostics for detection and prevention. Institut Pateur Korea strives to have fostering collaborations, partnerships, and educational outreach to share its knowledge and research know-how. Institut Pasteur Korea is a member of the Institut Pasteur International Network, which brings together 33 institutes located in 29 countries, united by the same mission, culture, and values. Leveraging vast human and scientific community, the Network is involved in international research projects, public health, teaching and training programs. By its diversity and global presence, the Institut Pasteur International Network aims to respond, in an innovative way, to international public health issues and priorities. ▲ There was introduction of current research status on MERS and Ebola virus infections. ▲ Dr. Mohamed Hachicha “Learning from MERS experience in Korea; immediate and complete isolation of suspected patients is a key step in containing an outbreak of a deadly pathogen. Equally important, understanding the routes of transmission is critical to completely block further spread of deadly viruses. Accordingly, these key elements should be considered in surveillance programs to manage and control infectious diseases” said Dr. Mohamed Hachicha, Executive Director of Discovery Biology Division. With respect to the identification of new mutations in the Korean MERS-CoV isolate, he added “Vaccine strategy may be limited by the genomic changes of the virus and alternative strategies should be considered to prevent and treat if the universal vaccine strategy fails to protect infected patients” Therefore, IPK is leveraging its proprietary discovery biology platforms in concert with the Institut Pasteur network to develop new small molecule therapeutics to treat infectious diseases. Dr. Hachicha also mentioned, “If engaged IPK is here to help Korea by deploying Institut Pasteur international task force to contain deadly viruses and avoid public health treat”. ▲ Dr. Ji-Young Min Dr. Ji-Young Min, Head of the Respiratory Viruses Research Laboratory at Institut Pasteur Korea and an expert on respiratory viruses commented, “Considering recent report from Saudi Arabia on the reoccurrence of MERS patients, there is a possibility of having additional MERS outbreak in Korea”. She added that IPK obtained the recent MERS-CoV isolate from Korea Centers for Disease Control and Prevention (KCDC) and embarked in the identification of novel small molecule drugs to treat MERS by blocking MERS-CoV entry, replication or release. She also stated that sequence alignment of the 2015 MERS-CoV with the virus isolated from Saudi Arabia in 2012 revealed mutations in 43 amino acids, suggesting that the development of universal MERS vaccine could be a challenge. Therefore our current effort to identify small molecule therapeutic agents may complement the vaccine strategy to tackle MERS. ▲ Dr. Marc P. Windisch “It is a question of time for Ebola reaching the Korean peninsula” said Dr. Marc P. Windisch, Head of the Hepatitis Research Laboratory. “Global warming significantly expands the territory of the fruit bat, the virus natural host, to the northern hemisphere. In addition, globalization, heavy air travel, will significantly increase the risks of emergent infectious diseases.” According to the WHO data, China already documented Ebola virus infections in pigs, however no human cases have been reported yet. “My team is actively working on the identification of potential Ebola virus interventions by utilizing a state-of-the-art cell culture system for Ebola developed by the US NIH. The system will accelerate the identification of new drugs, because it enables screening for small molecule inhibitors in a low biosafety level containment, meaning no authentic virus is being produced” commented Dr. Windisch. Small molecules with the appropriate pharmacological profile will be tested against authentic virus infection in BSL-4 facilities in the US, France, Germany or Australia.